GLITASCOT
PIOGLITAZONE · by SCOTMANN
Composition
Tab 15 mg/30 mg/45 mg: Pioglita zone (as NCI) 15mg/50 mg/45 mg.
Indications & Dosage
Type 2 diabetes mellitus alone or combined with metformin or a sulfonylurea, or with both, or with insulin: Adult: Initially 15-30 mg once daily, adjusted according to response to 45 mg once daily, in elderly patients, initiate with lowest possible dose and increase gradually; review treatment after 3-6 months and regularly thereafter for risk-benefits assessment. Dosage of concomitant sulfonylurea or insulin may need to be reduced. Children: Not recommended.
Contraindications
History of heart failure, previous or active bladder cancer, uninvestigated macroscopic haematuria, dialysis, diabetic ketoacidosis, pregnancy and lactation.
Precautions
Porphyrias, Monitor for fluid retention or other signs of cardiac failure (discontinue if deteriorates). Monitor for signs of hepatic dysfunction and check liver enzymes prior to therapy and every 2 months thereafter, elderly, risk of bone fracture and bladder cancer particularly in women and elderly.
Interactions
Insulin (contraindicated), NSAIDs, gemfibrozil, rifampicin.
Pregnancy
Contraindicated or not recommended
Lactation
Contraindicated or not recommended.
Side Effects
GI disturbances, anaemia, arthralgia, dizziness, haematuria, headache, hypoaesthesia, impotence, oedema, vertigo, visual disturbances, weight gain, altered blood lipids, bladder cancer, fatigue, hypoglycaemia, insomnia, proteinuria, sweating. Rare: Liver dysfunction.